Assessment of carotid atherosclerotic plaque vulnerability with multi-radiotracer PET/CT: a scoping review
摘要
Atherosclerotic carotid artery disease (CarAD) is a significant contributor to the global burden of cerebrovascular diseases. Several positron emission tomography computed tomography (PET/CT) radiotracers showed promising results in identifying and assessing vulnerable carotid atherosclerotic plaque. This review aims to assess the current evidence surrounding the use and potential of multiple PET radiotracers in identifying vulnerable carotid atherosclerotic plaque.
Materials and methodsA scoping review of the literature was conducted for original peer-reviewed articles of PET studies published between 2010 and 2024 that used 18F-fluorodeoxyglucose (18F-FDG), 18F-sodium fluoride (18F-NaF), 18F-fluoromisonidazole (18F-FMISO), 68Ga-DOTATATE, 68Ga-Pentixafor, and 11C-Acetate for the evaluation of vulnerable carotid atherosclerotic plaque. The Covidence platform facilitated the screening of articles and data extraction.
Results37 studies matched the inclusion criteria. Seven (19%) included serial dual-tracer PET/CT with 18F-FDG/18F-NaF, 18F-FDG/18F-FMISO, 18F-FDG/68Ga-DOTATATE, and 18F-FDG/68Ga-Pentixafor. The remaining studies used PET/CT 18F-FDG (N = 26, 70%), 18F-NaF (N = 2, 5%), 11C-Acetate (N = 1, 3%) and 68Ga-DOTATATE (N = 1, 3%). Substantial variation in PET/CT acquisition parameters such as uptake time (min) [18F-FDG: 50–180, 18F-NaF: 60–180, and 68Ga-DOTATATE: 60–120], radiotracer dose (MBq) [18F-FDG: 185–555, 18F-NaF: 125–370] and analysis methods [target-to-background ratio and/or standardised uptake values] were observed with no clear consensus on what constitutes a standard approach for carotid plaque evaluation using PET/CT.
ConclusionThe use of multiple PET radiotracers may provide novel diagnostic insights into the diagnosis of CarAD and improve the identification of vulnerable carotid atherosclerotic plaque. However, protocol heterogeneity affects reproducibility, necessitating standardised imaging parameters and histological validation to enable future clinical use of PET for CarAD assessment.
Key Points